NEW YORK, Aug. 30 /PRNewswire-FirstCall/ -- Pfizer Inc said today that
a Norwegian court decision has no practical effect on the company's ability
to protect Lipitor from the launch of a competitor generic product in
Norway by Ranbaxy.
"While we plan to appeal this decision, it's important to understand
that Lipitor continues to be protected from generic competition in Norway
through February 2009," said Peter Richardson, Pfizer's senior vice
president, associate general counsel and chief of intellectual property.
"In other major European markets Lipitor is protected by basic patents
expiring in 2011."
Pfizer's '706 patent, which was upheld in Norway last year as valid and
infringed by Ranbaxy, remains in effect until February 2009. Ranbaxy's
appeal of that decision is scheduled to be heard next March.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html /
CONTACT:
Bryant Haskins of Pfizer Inc, +1-212-733-8719
|
